A randomized, open-label, parallel-design, multicenter, Phase III study to compare the safety and efficacy of a fixed dose combination of SULBACTOMAX Vs CEFTRIAXONE in the treatment of hospitalized adult patients with Community-Acquired Pneumonia

Trial Profile

A randomized, open-label, parallel-design, multicenter, Phase III study to compare the safety and efficacy of a fixed dose combination of SULBACTOMAX Vs CEFTRIAXONE in the treatment of hospitalized adult patients with Community-Acquired Pneumonia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Ceftriaxone/sulbactam (Primary) ; Ceftriaxone
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Acronyms LRTI2011KR
  • Sponsors Korea Pharma
  • Most Recent Events

    • 11 Dec 2013 Planned number of patients changed from 124 to 248 as reported by Korean Clinical Trials Register record.
    • 10 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top